Bioceltix: Revolutionizing Vet Medicine with €2.5m Funding

Bioceltix, a biotech startup based in Wrocław, Poland, has received €2.5 million in funding from the European Funds for a Modern Economy program and has partnered with the Polish Agency for Enterprise Development. The company specializes in stem cell-based veterinary medicines, with a focus on treating atopic dermatitis in dogs. Bioceltix is planning to conduct an independent clinical trial across 20 clinics in Hungary, Portugal, Ireland, and Poland to test the safety and effectiveness of their product. Poland has been making strides in the biotech sector, with government support and funding for research projects and technological advancements.